

2nd Meeting
European
Myeloma Network

EMN



Program

Virtual | March 3-6, 2021

FACULTY

Annalisa	Bernardini	Turin, Italy	Eline	Menu	Brussels, Belgium
Juan	Bladé	Barcelona, Spain	Paolo	Milani	Pavia, Italy
Mario	Boccadoro	Turin, Italy	Monique C.	Minnema	Utrecht, The Netherlands
Niccolò	Bolli	Milan, Italy	Mohamad	Mohty	Paris, France
Frank	Bridoux	Poitiers, France	Philippe	Moreau	Nantes, France
Annemieke	Broijl	Rotterdam, The Netherlands	David L.	Murray	Rochester, USA
Michele	Cavo	Bologna, Italy	Inger S.	Nijhof	Amsterdam, The Netherlands
Gordon	Cook	Leeds, United Kingdom	Michael	O'Dwyer	Galway, Ireland
Faith E.	Davies	New York, USA	Enrique M.	Ocio	Santander, Spain
Michel	Delforge	Leuven, Belgium	Bruno	Paiva	Pamplona, Spain
Christoph	Driessens	St. Gallen, Switzerland	Giovanni	Palladini	Pavia, Italy
Brian G.M.	Durie	North Hollywood, USA	Charlotte	Pawlyn	London, United Kingdom
Corien M.	Eeltink	Amsterdam, The Netherlands	Torben	Plesner	Vejle, Denmark
Hermann	Einsele	Würzburg, Germany	Marc-Steffen	Raab	Heidelberg, Germany
Francesca	Gay	Turin, Italy	Noopur	Raje	Boston, USA
Hartmut	Goldschmidt	Heidelberg, Germany	Leo	Rasche	Würzburg, Germany
Roman	Hajek	Ostrava, Czech Republic	Paula	Rodriguez Otero	Pamplona, Spagna
Graham	Jackson	Newcastle upon Tyne, United Kingdom	Fredrik Hellem	Schjesvold	Oslo, Norway
Martin	Kaiser	London, United Kingdom	Hans	Scheurer	Brussels, Belgium
Efstathios	Kastritis	Athens, Greece	Pieter	Sonneveld	Rotterdam, The Netherlands
Marie Josee	Kersten	Amsterdam, The Netherlands	Evangelos	Terpos	Athens, Greece
Lla - Lanny	Kirsch	Seattle, USA	Steven P.	Treon	Boston, USA
Sigurdur	Kristinsson	Stockholm, Sweden	Saad	Usmani	Charlotte, USA
Alessandra	Larocca	Turin, Italy	Niels	van de Donk	Amsterdam, The Netherlands
Xavier	Leleu	Poitiers, France	Katja Christina	Weisel	Hamburg, Germany
Sagar	Lonial	Atlanta, USA	Elena	Zamagni	Bologna, Italy
Heinz	Ludwig	Wien, Austria	Sonja	Zweegman	Amsterdam, The Netherlands
Maria-Victoria	Mateos	Salamanca, Spain			

WEDNESDAY, MARCH 3, 2021

15.00-15.15 **OPENING CEREMONY**

15.15-16.00 **FROM MGUS TO SMM TO MM:
FROM BENCH TO BEDSIDE**

Chairpersons: S. Kristinsson, S. Lonial

The role of the immunemicroenvironment in evolving myeloma precursor states - **N. Bolli**

The biology and treatment of MGUS of clinical significance - **M.C. Minnema**
SMM: what is it and how to treat? - **S. Lonial**

16.15-17.00 **FROM BENCH TO BEDSIDE SESSION
GENOMICS IN MM**

Chairpersons: B. Paiva, P. Sonneveld

Short introduction of an expert in the field setting the stage - **P. Sonneveld**
What is high risk disease? - **M. Kaiser**
Are we ready to make a change in the treatment of high risk disease? - **C. Pawlyn**

17.15-18.15 **AMGEN SPONSORED SYMPOSIUM**

**The cycle of evolution in multiple myeloma management
what's around the next corner?**

Chairperson: K. Weisel

Introduction - **K. Weisel**

Guiding the way - Is it time for biomarker - driven treatment in myeloma? - **M. Kaiser**

At the crossroads - Retreat or switch? - **K. Weisel**

On the horizon - Novel models of interaction between patient and care team - **H. Ludwig**

Discussion

18.30-19.15 **RESPONSE MONITORING IN MULTIPLE MYELOMA**

Chairpersons: H. Ludwig, B. Paiva

M-protein detection; a matter of mass or velocity? - **D. Murray**
MRD detection - how, when and what then? - **B. Paiva**
Shedding light by PET-scans? - **E. Zamagni**

THURSDAY, MARCH 4, 2021

14.00-15.00 **ELDERLY PATIENTS WITH MYELOMA**

Chairpersons: M. Boccadoro, S. Zweegman

Short introduction by an expert in the field to set the stage - **S. Zweegman**
How to treat fit non-Tx eligible patients? - **M. Boccadoro**
How to treat unfit and frail patients - **A. Larocca**
Novel trial designs based on aging instead of age? - **G. Cook**

15.15-16.15 **YOUNG PATIENTS WITH MYELOMA**

Chairpersons: P. Moreau, P. Sonneveld

Short introduction by an expert in the field to set the stage - **M. Cavo**
First line treatment - **F. Gay**
To maintain or not and how? - **G. Jackson**
Optimal treatment sequences at relapse - **P. Moreau**

16.30-17.30 **JANSSEN SPONSORED SYMPOSIUM**

Managing patients with MM, now and in the new normal

Chairpersons: M.V. Mateos, S. Zweegman

Welcome and introduction - **S. Zweegman**
Advances in frontline management - **S. Zweegman**
Panel discussion: **F. Gay, P. Rodríguez Otero**
Novel agents in R/R MM management - **M.V. Mateos**
Panel discussion: **F. Gay, P. Rodríguez Otero**

17.45-18.30 **SPECIAL CONDITIONS - WALDENSTRÖM MACROGLOBULINEMIA**

Chairpersons: E. Kastritis, S.P. Treon

Biology of the disease - from genotype to phenotype? - **S.P. Treon**
Treatment in front line - **E. Kastritis**
Treatment at relapse - **M.J. Kersten**

18.45-19.15 **PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALK**

Chairperson: **B. Durie**

IMF - USA - **B. Durie**
MPE - Myeloma patient groups across Europe - **H. Scheurer**

FRIDAY, MARCH 5, 2021

12.45-13.45 MEET THE EXPERT

Simultaneous sessions in 3 virtual rooms

- Management of MM patients from a nurse's perspective
A. Bernardini, C. Eeltink
 - Aggressive disease in daily practice
A. Broijl, K. Weisel
 - RRMM in daily practice
C. Driessen, H. Goldschmidt
- VIRTUAL ROOM 1**
- VIRTUAL ROOM 2**
- VIRTUAL ROOM 3**

14.00-14.30 FROM BENCH TO BEDSIDE SESSION - MOVING OUT OF THE MARROW

Chairpersons: F. Gay, M. Kaiser

- Plasma cell leukemia - different biology, different treatment? - **S. Usmani**
Does extramedullary means extra treatment? - **X. Leleu**

14.45-15.30 SPECIAL CONDITIONS

AL AMYLOIDOSIS & LIGHT CHAIN DEPOSITION DISEASE

Chairpersons: E. Kastritis, G. Palladini

- AL Amyloidosis: mechanisms of disease and biomarkers - **G. Palladini**
Early diagnosis and optimal treatment - **P. Milani**
Diagnosis and management of light chain deposition disease - **F. Bridoux**

15.45-16.45 SANOFI SPONSORED SYMPOSIUM

Management of relapsed and refractory multiple myeloma with novel monoclonal antibody-based regimens: from evidence based considerations to clinical practice

Chairpersons: P. Moreau, P. Sonneveld

- Welcome and introduction - **P. Moreau**
Mechanisms of actions of CD38 monoclonal antibodies - **N. Van de Donk**
Optimization of the treatment sequence with available treatments in lenalidomide refractory multiple myeloma patients - Level of evidence - **E. Ocio**
AntiCD38 monoclonal antibody therapy in combinations with pomalidomide and dexamethasone - Level of evidence - **X. Leleu**
Discussion and closing remarks

17.00-18.00 DEBATE SESSION

Chairpersons: F. Davies, M. Mohty

- Should all elderly receive daratumumab in first line? - YES - **M.V. Mateos** vs NO - **S. Zweegman**
- Switch induction or go directly to transplant in case of suboptimal response? **F. Schjesvold** (directly to transplantation) vs **R. Hajek** (switch induction)
- Do all MGUS patients need follow-up? - YES - **S. Kristinsson** vs NO - **J. Bladé**

18.15-19.00 SPECIAL ATTENTION TO

Chairpersons: H. Ludwig, I. Nijhof

- Bone disease - **E. Terpos**
Cytokine release syndrome and neurologic symptoms with novel immune therapy - **N. Rajeev**
From bacteria to viruses - **M. Delforge**

SATURDAY, MARCH 6, 2021

12.45-13.45 MEET THE EXPERT

Simultaneous sessions in 2 virtual rooms

- SMM to treat or not
A. Broijl, S. Lonial
- Frail patients in daily practice
A. Larocca, I. Nijhof

VIRTUAL ROOM 4

VIRTUAL ROOM 5

14.00-14.40 SPONSORED LECTURES

Chairmen: **M. Boccadoro, G. Cook**

- LECTURE SPONSORED BY ADAPTIVE:

Application of Immunosequencing for MRD Determination - **L. Kirsch**

- LECTURE SPONSORED BY GSK:

Recent advances in approved and investigational agents targeting B-cell maturation antigen (BCMA) for relapsed/refractory multiple myeloma (RRMM)
R. Popat

15.00-15.45 JOINT EMN-EHA SYMPOSIUM

Chairpersons: **M.V. Mateos, N. van de Donk**

Immune therapy from rationale to treatment - **P. Sonneveld**

Current evidence for bispecifics in MM treatment - **H. Einsele**

Current evidence for CARt cells in MM treatment - **P. Rodriguez-Otero**

16.00-17.00 BEST ABSTRACTS - ORAL PRESENTATIONS

Chairpersons: **C. Driessen, M. Raab, F. Schjesvold, K. Weisel**

B01

INTEGRATED SYSTEMS-LEVEL ANALYSIS OF PROTEOTOXIC STRESS RECOVERY REVEALS DRUGGABLE METABOLIC VULNERABILITIES OF PROTEASOME INHIBITOR-RESISTANT MYELOMA CELLS
Saavedra-Garcia P., Roman-Trufero M., Al-Sadah H., Lopez-Jimenez E., Christoforou M., Penfold L., Parzych K., Caputo V., Blighe K., Kaiser M.F., Piazza P., Capece D., Xiong X., Miao Y., Encheva V., Thiel D., Liu Z., Snijders A.P., Franzoso G., Chaidos A., Karadimitris A., Keun H.C., Oyarzun D., Barahona M., Auner H.W. (London, Sutton, Edinburgh)

B02

RUXOLITINIB COMBINED WITH THE MCL-1 INHIBITOR S63845 IS HIGHLY EFFICIENT IN TREATING MYELOMA IN THE INA-6 XENOGRAFT MODEL
Gramatzki M., Otte A.K., Brdon J.W., Günther A., Peipp M., Burger R. (Kiel)

B03

HIGH LEVELS OF CIRCULATING PLASMA CELLS (CPC) ARE AN INDEPENDENT HIGH-RISK FEATURE BUT ARE MODULATED BY MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS TREATED WITH NOVEL AGENTS
Bertamini L., Grasso M., D'Agostino M., Pascarella A., Tosi P., Monaco F., Pisani F., Bertazzoni P., Gilestro M., Capra A., Galieni P., Annibali O., Pavone V., Molica S., Ronconi S., Tacchetti P., Musto P., Gay F., Boccadoro M., Oliva S. (Torino, Cuneo, Venezia Mestre, Rimini, Alessandria, Roma, Milano, Ascoli Piceno, Tricase, Catanzaro, Meldola, Bologna, Bari)

B04

UNRAVELLING DRUG RESISTANCE AND SENSITIZATION TO PROTEASOME INHIBITORS USING GENOME-WIDE CRISPR-CAS9 KNOCKOUT SCREENING

Vlaien S., Kint N., De Keersmaecker K., Daelemans D., Delforge M. (*Leuven*)

B05

DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-Rd) VERSUS LENALIDOMIDE AND DEXAMETHASONE (Rd) IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FRAILTY SUBGROUP ANALYSIS OF MAIA

Zweegman S., Usmani S., Hulin C., Kumar S., Plesner T., Touzeau C., Bahlis N., Basu S., Nahm H., Goldschmidt H., Quach H., Cook G., Mohty M., Venner C., Weisel K., Raje N., Hebraud B., Belhadj-Merzoug K., Benboubker L., Decaux O., Manier S., Caillot D., Pei H., Van Rampelbergh R., Uhlar C., Kobos R., Facon T. (*Amsterdam, Charlotte, Pessac, Rochester, Vejle, Nantes, Calgary, Wolverhampton, Stockholm, Heidelberg, Melbourne, Leeds, Paris, Edmonton, Hamburg, Boston, Toulouse, Creteil, Tours, Rennes, Boston, Dijon, Titusville, Beerse, Spring House, Raritan, Lille*)

B06

PREDICTORS OF EARLY RELAPSE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: INTEGRATED ANALYSIS OF BASELINE FEATURES AND ACHIEVEMENT OF MINIMAL RESIDUAL DISEASE NEGATIVITY

Bertamini L., Zaccaria G.M., Offidani M., Vozella F., Becco P., Belotti A., Capra A., Galli M., Morabito F., Pisani F., Galieni P., Rizzi R., Gozzetti A., Pescosta N., De Rosa L., Narni F., Gilestro M., Palmieri S., Cea M., Tosi P., Giuliani N., Musto P., Cavo M., Boccadoro M., Gay F. (*Torino, Ancona, Roma, Candiolo, Brescia, Bergamo, Cosenza, Ascoli Piceno, Bari, Siena, Bolzano, Modena, Napoli, Genova, Rimini, Parma, Rionero in Vulture, Bologna*)

B07

TREATMENT EMERGENT PERIPHERAL NEUROPATHY IN THE CASSIOPEIA TRIAL

Fokkema C., Van Der Holt B., van Duin M., Wester R., Cupedo T., Moreau P., Vermeulen J., Broyl A., Sonneveld P. (*Rotterdam, Nantes, Leiden*)

B08

REVEALING TRANSCRIPTOME DEREGRULATION UPON GENOMIC COMPLEXITY IN MULTIPLE MYELOMA

Da Vià M.C., Ziccheddu B., Maeda A., Morlupi S., Dugo M., Todoerti K., Oliva S., D'Agostino M., Landgren O., Iorio F., Pettine L., Pompa A., Manzoni M., Lionetti M., Corradini P., Baldini L., Neri A., Maura F., Bolli N. (*Milan, Turin, New York, Cambridge*)

B09

TREATMENT INDUCED CYTOTOXIC T-CELL MODULATION IN MULTIPLE MYELOMA PATIENTS

Barilà G., Pavan L., Vedovato S., Berno T., Arangio Febbo M., Lo Schirico M., Teramo A., Calabretto G., Vicenzetto C., Gasparini V.R., Fregnani A., Manni S., Trimarco V., Carraro S., Facco M., Piazza F., Semenzato G., Zambello R. (*Padova*)

B10

CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Madduri D., Berdeja J., Usmani S., Jakubowiak A., Agha M., Cohen A., Stewart A., Hari P., Htut M., O'Donnell E., Munshi N., Avigan D., Deol A., Lesokhin A., Singh I., Zudaire E., Yeh T.M., Allred A., Olyslager Y., Banerjee A., Goldberg J., Schechter J., Jackson C., Deraedt W., Zhuang S., Infante J., Geng D., Wu X., Carrasco-Alfonso M., Akram M., Hossain F., Rizvi S., Fan F., Jagannath S., Lin Y., Martin T. (*New York, Nashville, Charlotte, Chicago, Pittsburgh, Philadelphia, Toronto, Milwaukee, Duarte, Boston, Detroit, Spring House, Raritan, Beerse, Piscataway, Nanjing, Rochester, San Francisco*)

B11

TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS
Garfall A., Usmani S., Mateos M.V., Nahi H., van de Donk N., San-Miguel J., Oriol A., Rosinol L., Chari A., Bhutani M., Pei L., Verona R., Grgis S., Stephenson T., Goldberg J., Banerjee A., Krishnan A. (*Philadelphia, Charlotte, Salamanca, Stockholm, Amsterdam, Navarra, Barcelona, New York, Spring House, Duarte*)

B12

TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM AN ONGOING PHASE 1 STUDY
Oriol A., Berdeja J., Chari A., van de Donk N., Rodriguez-Otero P., Askari E., Mateos M.V., Minnema M., Verona R., Grgis S., Prior T., Hilder B., Russell J., Goldberg J., Krishnan A. (*Barcelona, Nashville, New York, Amsterdam, Navarra, Madrid, Salamanca, Utrecht, Spring House, Duarte*)

B13

ELOTUZUMAB ELIMINATES IMMUNOSUPPRESSIVE CD8+ CD28- T CELLS IN PATIENTS WITH MULTIPLE MYELOMA (GMMG HD6 CLINICAL TRIAL)
Awwad M.H.S., Mahmoud A., Bruns H., Echchannaoui H., Kriegsmann K., Raab M.S., Bertsch U., Munder M., Jauch A., Weisel K., Maier B., Salwender H.J., Eckstein V., Hänel M., Fenk R., Dürig J., Brors B., Benner A., Müller-Tidow C., Goldschmidt H., Hundemer M. (*Heidelberg, Erlangen, Mainz, Tübingen, Hamburg, Chemnitz, Düsseldorf, Essen*)

B14

TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIGH-RISK PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FEASIBILITY AND PRELIMINARY RESULTS FROM THE VALENCIAN GREMI STUDY GROUP

Jiménez Castillo M., Rubio Lopes-García L., Pérez Rodríguez P.L., Legarda Campo M., Ríos Rodríguez S.J., Francés Aracil E., Blanes Company M., Cejalvo Andújar M.J., Pedreño Miñana M.J., García Feria A., García Romero Domínguez S., Ribas García P., Donato Martín E., Fernández Llavador M.J., Fernández Zarzoso M., Gómez Beltrán E., Juan Marco M.L., Marco Buades J.E., Panero Ruiz M., Sayas Lloris M.J., De la Rubia Comos J. (*Valencia, Elche, Elda, Requena, Valencia*)

B15

AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION
Cooper A., Khaliq N., Kelly G., Bulger P., Rocci A. (*Manchester*)

B16

APPLICATION OF RISK MODELS FOR SMOULDERING MYELOMA TO A REAL WORLD, SINGLE CENTRE, COHORT
Ainley L., Camilleri M., Chavda S., Mcmillan A., Lee L., Popat R., Sillito F., Yong K. (*London*)

17.15-18.00 **FROM BENCH TO BEDSIDE SESSION - IMMUNESYSTEM IN MM**

Chairpersons: M. O'Dwyer, T. Plesner

Short introduction of an expert in the field setting the stage - **T. Plesner**

The biology of immune resistance in MM - **L. Rasche**

How to overcome immune resistance in MM - **N. van de Donk**

18.15-19.00 **FROM BENCH TO BEDSIDE SESSION
FROM THE MICROENVIRONMENT TO OVERCOMING DRUG RESISTANCE**

Chairpersons: E. Menu, E. Ocio

Short introduction of an expert in the field setting the stage - **E. Menu**

The myeloma microenvironment in drug resistance - **E. Menu**

How to overcome microenvironment induced drug resistance and
novel agents in heavily pre-treated patients - **E. Ocio**

19.00-19.15 **CONCLUSION & FINAL GREETINGS**

POSTER

1. BIOLOGY AND PRECLINICAL

P01

TARGETING MONOCARBOXYLATE TRANSPORTER 4 REDUCES MYELOMA CELL VIABILITY IN VITRO

Van Droogenbroeck L., Oudaert I., Maes A., Satilmis H., Vlummens P., Vandewalle N., Fendt S., Maes K., De Bruyne E., Vanderkerken K., De Veirman K., Menu E. (Brussels, Gent, Leuven)

P02

THE CROSS-REGULATION BETWEEN TLR4 AND HO-1/CO SIGNALING PATHWAYS WORKS AS STRESS-RESPONSIVE MECHANISM TO INCREASE UPR RESPONSE AND PROTECT MITOCHONDRIA PROMOTING BORTEZOMIB RESISTANCE

Tibullo D., Scandura G., Giallongo C., Barbato A., La Spina E., Cambria D., Dulcamare I., Romano A., Parrinello N.L., Palumbo G.A., Li Volti G., Di Raimondo F. (Catania)

P03

IDENTIFICATION OF NOVEL CRUCIAL REGULATORS OF IMMUNOGLOBULIN PRODUCTION IN MULTIPLE MYELOMA

Vdovin A., Jelinek T., Sahinbegovic H., Durech M., Sevcikova T., Hrdinka M., Hajek R., Simicek M. (Ostrava)

P04

INHIBITION OF TLR4 SIGNALING OVERCOMES BORTEZOMIB RESISTANCE IN MYELOMA PLASMA CELLS AFFECTING MITOCHONDRIAL FITNESS

Giallongo C., Tibullo D., Puglisi F., Barbato A., Romano A., Cambria D., La Spina E., Parrinello N., Conticello C., Amorini A., Li Volti G., Lazzarino G., Palumbo G.A., Di Raimondo F. (Catania)

P05

METABOLIC ADAPTATION OF MYELOMA CELLS TO TRYPTOPHAN DEPRIVATION

Romano A., Parrinello N.L., Scandura G., Puglisi F., Giallongo C., Barbato A., La Spina E., Tibullo D., Orfanelli U., Cenci S., Di Raimondo F. (Catania, Milano)

P06

A CANCER-RELATED MicroRNA SIGNATURE PREDICTS OSTEOLYtic DISEASE AND EXHIBITS PROGNOSTIC POTENTIAL IN MULTIPLE MYELOMA

Papanota A.M., Karousi P., Kontos C.K., Liacos C., Artemaki P.I., Patseas D., Papadimitriou M., Eleutherakis-Papaiaakovou E., Avgeris M., Kanellias N., Bagratuni T., Roussou M., Dialoupi I., Kastritis E., Gavriatopoulou M., Scorilas A., Dimopoulos M.A., Terpos E. (Athens)

P07

IMMUNOSUPPRESSIVE BONE MARROW MICROENVIRONMENT INDUCED BY MULTIPLE MYELOMA-DERIVED EXTRACELLULAR VESICLES

Lopes R., Caetano J., Barahona F., Ferreira B., Pestana C., Carneiro E., João C. (Lisbon)

P08

EXOME AND TRANSCRIPTIONAL PROFILING OF ABERRANT PLASMA CELLS IN LIGHT-CHAIN AMYLOIDOSIS AND MULTIPLE MYELOMA

Sevcikova T., Chyra Z., Vojta P., Puterova J., Brozova L., Zatopkova M., Grosicki S., Pour L., Stork M., Harvanova L., Mistrik M., Mikala G., Robak P., Czyz A., Debski J., Usnarska-Zubkiewicz L., Jurczyszyn A., Morgan G., Kryukov F., Budinska E., Simicek M., Jelinek T., Hrdinka M., Hajek R. (Ostrava, Boston, Olomouc, Brno, Katowice, Bratislava, Budapest, Lodz, Wroclaw, Cracow, New York)

P09

tRNA-DERIVED RNA FRAGMENTS IN PLASMA CELLS: PROMISING MOLECULAR BIOMARKERS OF PROGNOSIS IN MULTIPLE MYELOMA

Karousi P., Papanota A.M., Kontos C.K., Liacos C., Artemaki P.I., Patseas D., Liosi A.A., Mavrianou-Koutsoukou N., Kalioraki M.A., Fotiou D., Ntanasis-Stathopoulos I., Migkou M., Malandrakis P., Gavriatopoulou M., Kastritis E., Scorilas A., Dimopoulos M.A., Terpos E. (*Athens*)

P10

THE IMPACT OF BETA-BLOCKERS ON MULTIPLE MYELOMA CELL SURVIVAL

Satilmis H., Verheyen E., Oudaert I., Vandewalle N., Fan R., De Bruyne E., Maes A., Menu E., Vanderkerken K., De Veirman K. (*Brussels*)

P11

TARGETING LACTATE PATHWAY IN TUMOR MICROENVIRONMENT (TME) MAY BE A POTENTIAL STRATEGY FOR ANTI-CANCER THERAPY IN MULTIPLE MYELOMA

Barbato A., Giallongo C., Tibullo D., Romano A., Di Raimondo F. (*Catania*)

P12

BEHAVIOUR OF CIRCULATING ENDOTHELIAL CELLS (CECs) DURING AUTOLOGOUS STEM CELLS TRANSPLANTATION (AuSCT) IN PATIENTS WITH MULTIPLE MYELOMA

Annibali O., Gregorj C., Tomarchio V., Di Cerbo M., Antonelli L., Armiento D., Scardocci A., Tafuri M., Circhetta E., Sarlo C., Vincenzi B., Tirindelli M.C., Avvisati G. (*Roma*)

P13

LIGHT CHAIN MULTIPLE MYELOMA FOLLOW UP: SERUM IMUNOFIXATION VS SERUM FREE LIGHT CHAIN

Pires A., Duarte D., Chacim S., Azevedo C., Barreto J., Godinho I., Sousa E., Palmeira C., Tavares M., Pereira D., Moreira C., Espírito-Santo A., Moreira I., Domingues N., Oliveira I., Martins A., Viterbo L., Mariz J., Martins G. (*Porto*)

2. NEWLY DIAGNOSED MULTIPLE MYELOMA

P14

HIGH-RISK MULTIPLE MYELOMA PATIENTS ARE MISSED WITHOUT GENE EXPRESSION PROFILING

Van Vliet M., Chen Y., Van Beers E.H., Kuiper R., Valent E., Spaan M., Terragna C., Zamagni E., Cavo M., Oliva S., Larocca A., Haferlach T., Chng W., Waage A., Zweegman S., Sonneveld P. (*Rotterdam, Bologna, Turin, Munich, Singapore, Trondheim, Amsterdam*)

P15

IMPACT OF GAIN AND AMPLIFICATION OF 1Q IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS RECEIVING CARFILZOMIB-BASED TREATMENT IN THE FORTE TRIAL

D'Agostino M., Ruggeri M., Aquino S., Giuliani N., Arigoni M., Gentile M., Olivero M., Vincelli I.D., Capra A., Mussatto C., Ledda A., Tacchetti P., Musolino C., Cellini C., Patriarca C., Ballanti S., Calogero R., Musto P., Boccadoro M., Gay F. (*Torino, Genova, Parma, Cosenza, Reggio Calabria, Cagliari, Bologna, Messina, Ravenna, Udine, Perugia, Bari*)

P16

MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) AND NEXT-GENERATION SEQUENCING (NGS) IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (NDMM): RESULTS FROM THE FORTE TRIAL

Oliva S., Genuardi E., Petrucci M.T., D'agostino M., Auclair D., Spadano A., Jacob A.P., Cea M., De Rosa L., Gozzetti A., Ruggeri M., Capra A., Gilestro M., Pescosta N., Palmas A.D., Siniscalchi A., Kirsch I.R., Corradini P., Musto P., Boccadoro M., Zamagni E., Gay F. (*Torino, Roma, Norwalk, Pescara, Seattle, Genova, Siena, Bolzano, Nuoro, Milano, Bari, Bologna*)

P17

SINGLE VS DOUBLE TRANSPLANTATION OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL LIFE ANALYSIS

Morè S., Corvatta L., Maracci L., Mancini G., Scortechini I., Olivieri A., Offidani M. (*Ancona*)

P18

PROGNOSTIC VALUE OF THE MINIMAL RESIDUAL DISEASE (MRD) MONITORING BY NOVEL NEXT-GENERATION FLOW (NGF) AND HEAVY + LIGHT CHAIN (HLC) IMMUNOASSAYS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM). RESULTS FROM THE VALENCIAN GRUPO DE ESTUDIOS DE MIELOMMA (GREMI), SPAIN

Remigia M.J., Sempere A., Solano C., Teruel A.I., Quiñones C., Arnao M., Marco M.J., Romero S., Amat P., Ruiz M.A., Avaria A., Ribas P., Cordon L., Andreu R., Cejalvo M.J., Blanes M., Tarin F., Pérez P.I., Carbonell-Asíns J.A., De la Rubia J. (*Valencia, Gandia, Elda, Alicante*)

P19

COST EFFECTIVENESS OF NOVEL AGENTS IN THE TREATMENT OF MULTIPLE MYELOMA:

A SYSTEMATIC REVIEW

McCulloch S., Perry S. (*Calgary, Vancouver*)

P20

PROGNOSTIC IMPACT OF RAPID REDUCTION OF INVOLVED LIGHT CHAIN DURING FIRST LINE THERAPY WITH BENDAMUSTINE, PREDNISONE AND BORTEZOMIB (BPV) IN MYELOMA PATIENTS

Holzhey T., Pönisch W., Wang S., Holzvogt M., Holzvogt B., Andrea M., Platzbecker U., Scholz M. (*Leipzig*)

P21

R2-ISS, A NEW RISK STRATIFICATION MODEL IN NEWLY DIAGNOSED MULTIPLE MYELOMA BY THE EUROPEAN MYELOMA NETWORK WITHIN HARMONY BIG DATA PLATFORM PROJECT

D'Agostino M., Lahuerta J.J., Wester R., Waage A., Bertsch U., Zamagni E., Mateos M.V., Larocca A., Dall'Olio D., van de Donk N.W.C.J., Cairns D., Rocchi S., Salwender H., Bladé J., van der Holt B., Castellani G., Ciccone G., Capra A., Dürig J., Bringhen S., Zweegman S., Cavo M., Goldschmidt H., Cook G., Hernandez Rivas J.M., San-Miguel J., Boccadoro M., Sonneveld P. (*Italy, Spain, the Netherlands, Norway, Germany, United Kingdom*)

P22

ON-DEMAND PLERIXAFOR FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA: A PRELIMINARY ANALYSIS OF THE OBSERVATIONAL STUDY MOZOBL06877

Mina R., Bonello F., Milone G., Fazio F., Nozzoli C., Bongarzoni V., Capra A., Marchesi F., Cetani G., Malfitano A., Rota-Scalabrini D., Ballanti S., Lemoli R.M., Tosi P., Derudas D., de Fabritiis P., Offidani M., Musto P., Corradini P., Cavo M., Boccadoro M., Larocca A. (*Torino, Catania, Roma, Firenze, Candiolo, Perugia, Genova, Rimini, Cagliari, Ancona, Bari, Milano, Bologna*)

P23

PREDICTIVE GENE EXPRESSION-BASED BIOMARKERS FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS

Valent E., Chen Y.T., van Duin M., Troia R., Pautasso C., Kuiper R., van Beers E., van Vliet M., Haferlach T., Chng W., Zweegman S., Oliva S., Larocca A., Sonneveld P. (*Rotterdam, Turin, Munich, Singapore, Amsterdam*)

P24

PROGNOSTIC SIGNIFICANCE OF DOUBLE AND TRIPLE HIT MULTIPLE MYELOMA: ULTRA HIGH-RISK ENTITIES?

Sretenovic A., Mitrovic M., Jovanovic J., Bukumiric Z., Djordjevic V., Dencic Fekete M., Jelicic J., Perunucic Jovanovic M., Terzic T., Bila J. (*Belgrade*)

P25

TOLERABILITY OF HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS OVER 70 YEARS: "GIMEMA WORKING GROUP LAZIO" EXPERIENCE

Rago A., Annibali O., Tomarchio V., Fiorini A., Fazio F., Coppetelli U., De Rosa L., Papa E., Bianchi M.P., Antolino G., Caravita di Toritto T. (*Roma*)

P26

LEN/DEX COMBINATION AS FIRST-LINE THERAPY OF FRAIL MULTIPLE MYELOMA PATIENTS:
A REAL LIFE STUDY

Leotta V., Bellofiore C., Markovic U., Romano A., Di Giorgio M.A., Bulla A., Moschetti G., Scirè P., Curtopelle A., Elia F., Del Fabro V., Di Raimondo F., Conticello C. (*Catania, Viagrande*)

P27

EFFICACY OF MAINTENANCE AND CONTINUOUS THERAPY IN PATIENTS WITH MULTIPLE
MYELOMA: INDEPENDENT NETWORK META-ANALYSIS

Luchinin A., Semochkin S. (*Kirov, Moscow*)

P28

IXAZOMIB-BASED INDUCTION FOLLOWED BY SINGLE-AGENT IXAZOMIB MAINTENANCE IN
TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS:
UPDATED RESULTS OF THE EMN10-UNITO TRIAL

Mina R., Larocca A., Corradini P., Cascavilla N., Liberati A.M., Pescosta N., Petrucci M.T., Ciccone G., Capra A., Patriarca F., Rota-Scalabrini D., Innao V., Bernardini A., Cea M., Zambello R., Monaco F., Belotti A., Cellini C., Galli M., Grasso M., Aquino S., Margiotta Casaluci G., De Sabbata G., Ballanti S., Offidani M., Mancuso K., Boccadoro M., Bringhen S. (*Torino, Milano, San Giovanni Rotondo, Terni, Bolzano, Roma, Udine, Candiolo, Messina, Genova, Padova, Alessandria, Brescia, Ravenna, Bergamo, Cuneo, Novara, Trieste, Perugia, Ancona, Bologna*)

P29

DARATUMUMAB TO ERADICATE MRD IN >VGPR MM PATIENTS AFTER FIRST LINE THERAPY:
INTERIM ANALYSIS OF THE DART4MM MULTICENTER ITALIAN STUDY

Gozzetti A., Raspadori D., Bacchiarri F., Pacelli P., Ciofini S., Caffarelli C., Antonioli E., Buda G., Sammartano V., Lombardo A., Galieni P., Occhini U., Liberati A.M., Staderini M., Sicuranza A., Tocci D., Crupi R., Bosi A., Petrini M., Bocchia M. (*Siena, Firenze, Pisa, Terni, Ascoli Piceno, Arezzo*)

P30

PHENOTYPIC AND PROGNOSTIC EVALUATION OF CIRCULATING PLASMA CELLS IN NEWLY DIAGNOSED
MULTIPLE MYELOMA DETECTED WITH NEXT GENERATION FLOW CYTOMETRY

Terpos E., Kostopoulos I.V., Papanota A.M., Papadimitriou K., Malandrakis P., Rousakis P., Ntanasis-Stathopoulos I., Fotiou D., Metousis A., Kanellias N., Migkou M., Eletherakis-Papaikovou E., Gavriatopoulou M., Kastritis E., Tsitsilonis O.E., Dimopoulos M.A. (*Athens, London*)

P31

TAILORING THERAPY FOR NEWLY DIAGNOSED HIGH-RISK MYELOMA PATIENTS – FIRST RESULTS
OF THE RISK-ADAPTED UMKRA OPTIMUM (MUK9) TRIAL

Jenner M., Hall A., Sherborne A., Walker K., Sharp K., Bowles K., Garg M., Lokare A., Ellis S., Jackson G., Flanagan L., Drayson M., deTute R., Owen R., Pratt G., Cook G., Brown S., Kaiser M. (*Southampton, Norwich, Leicester, Birmingham, Newcastle, Birmingham, Leeds, London*)

3. RELAPSED/REFRACTORY MULTIPLE MYELOMA

P32

DEPTH OF RESPONSE AND RESPONSE KINETICS OF ISATUXIMAB PLUS CARFILZOMIB AND
DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA: IKEMA INTERIM ANALYSIS

Martin T., Mikhael J., Hajek R., Kim K., Suzuki K., Hulin C., Garg M., Quach H., Sia H., George A., Konstantinova T., Risso M.L., Asset G., Macé S., van de Velde H., Moreau P. (*San Francisco, Phoenix, Ostrava, Seoul, Tokyo, Bordeaux, Leicester, Melbourne, Victoria, Tweed Heads, Wellington, Ekaterinburg, Vitry-Sur-Seine, Chilly-Mazarin, Cambridge, Nantes*)

P33

EFFECTS OF CARFILZOMIB ON BONE METABOLISM OF PATIENTS WITH RELAPSED/REFRACTORY
MULTIPLE MYELOMA – THE CARMMA STUDY

Terpos E., Ntanasis-Stathopoulos I., Katodritou E., Kyrtsonis M.C., Anagnostopoulos A., Spanoudakis E., Papatheodorou A., Eletherakis-Papaikovou E., Kanellias N., Gavriatopoulou M., Makras P., Kastritis E., Dimopoulos M.A. (*Athens, Thessaloniki, Alexandroupolis*)

P34

OUTCOME OF COVID-19 INFECTION AMONG MYELOMA PATIENTS ON LENALIDOMIDE MAINTENANCE

Kircali E., Cengiz Seval G., Koçak Toprak S., Arslan Ö., Topçuoğlu P., Özcan M., İlhan O., Gürman G., Beksaç M. (*Ankara*)

P35

RECOVERY OF OCULAR EVENTS WITH LONGER-TERM FOLLOW-UP IN THE DREAMM-2 STUDY OF SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Lonial S., Nooka A.K., Thulasi P., Badros A.Z., Jeng B.H., Callander N.S., Sborov D., Zaugg B.E., Popat R., Degli Esposti S., Byrne J., Opalinska J., Baron J., Piontek T., Gupta I., Dana R., Farooq A.V., Jakubowiak A. (*Atlanta, Baltimore, Madison, Salt Lake City, London, Upper Providence, Boston, Chicago*)

P36

HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN 55 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE—SUBGROUP ANALYSIS

Richardson P., Mateos M., Oriol A., Larocca A., Cavo M., Rodríguez-Otero P., Leleu X., Norkin M., Nadeem O., Hiemenz J., Hassoun H., Touzeau C., Alegre A., Paner A., Maisel C., Mazumder A., Raptis A., Puig N., Zamagni E., Thuresson M., Harmenberg J., Harlin O., Bladé J. (*Boston, Salamanca, Badalona, Torino, Bologna, Poitiers, Jacksonville, Boston, Gainesville, New York, Nantes, Madrid, Chicago, Dallas, Glendale, Pittsburgh, Stockholm*)

P37

HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EXPOSED TO PRIOR ALKYLATOR THERAPY—SUBGROUP ANALYSIS

Rodríguez-Otero P., Mateos M.V., Oriol A., Larocca A., Bladé J., Cavo M., Leleu X., Norkin M., Nadeem O., Hiemenz J., Hassoun H., Touzeau C., Alegre A., Paner A., Maisel C., Mazumder A., Raptis A., Puig N., Thuresson M., Harmenberg J., Harlin O., Richardson P. (*Pamplona, Salamanca, Badalona, Torino, Barcelona, Bologna, Poitiers, Jacksonville, Boston, Gainesville, New York, Nantes, Madrid, Chicago, Dallas, Glendale, Pittsburgh, Stockholm*)

P38

IMMUNE THROMBOCYTOPENIA ASSOCIATED WITH MULTIPLE MYELOMA

Kircali E., Cengiz Seval G., İlhan O., Gürman G., Beksaç M. (*Ankara*)

P39

DISTINCTIVE FEATURES OF THE TUMOR MICROENVIRONMENT IN DARATUMUMAB-NAÏVE vs -REFRACTORY PATIENTS MAY EXPLAIN THE DIFFERENTIAL RESPONSE TO ANTI-PDL1 AND ANTI-CD-38 COMBINATION TREATMENT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Raval A., Green C., Fritsch E.W., Ma C., Kockx M., Hamidi H., Huang H., Colburn D., Wong S.W., Adamkewicz J.I., Cho H.J. (*South San Francisco, Basel, Antwerp, Mississauga, San Francisco, New York*)

P40

PATIENT-REPORTED EXPERIENCES DURING AND FOLLOWING TREATMENT WITH BELANTAMAB MAFODOTIN (BELAMAF) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
IN THE DREAMM-2 STUDY

Eliason L., Correll J., Martin M., Cardellino A., Opalinska J., Piontek T., Gorsh B., Sapra S., Popat R. (*Upper Providence, Seattle, London*)

P41

ASSESSMENT OF EYE FUNCTION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): BASELINE OCULAR DATA FROM THE DREAMM-2 TRIAL

Popat R., Kazantzi A., Farooq A.V., Thulasi P., Lonial S., Jakubowiak A., Badros A.Z., Jeng B.H., Opalinska J., Baron J., Piontek T., Byrne J., Womersley L., Gupta I., Degli Esposti S. (*London, Chicago, Atlanta, Baltimore, Upper Providence*)

P42

ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE (DEX) AND DARATUMUMAB (DARA) OR BORTEZOMIB (BTZ) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
REFRACTORY TO AN IMID AND/OR A PROTEASOME INHIBITOR (PI) – UPDATED EFFICACY AND SAFETY

Ocio E., Efebera Y., Hájek R., Granell M., Maisnar V., Straub J., Eveillard J.R., Karlin L., Ribrag V., Mateos M.V., Oriol A., Sydsvander M., Norin S., Mannikko S., Pour L. (*Santander, Columbus, Ostrava, Barcelona, Hradec Králové, Brest, Pierre-Benite, Villejuif, Salamanca, Spain, Badalona, Stockholm, Brno*)

P43

DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF)
EFFECTS ON PATIENT-REPORTED OUTCOME (PRO) MEASURES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Popat R., Lonial S., Voorhees P.M., Degli Esposti S., Gupta I., Opalinska J., Sapra S., Gorsh B., He Z., Kleinman D., Schaumberg D., Loubert A., Meunier J., Regnault A., Eliason L. (*London, Atlanta, Charlotte, Upper Providence, Rochester, Salt Lake City, Lyon*)

P44

BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS' ERA

Cerchione C., Catalano L., Rocco S., Palmieri S., Nappi D., Pareto A.E., Ronconi S., Ceccolini M., Pane F., Martinelli G., Ferrara F. (*Meldola, Napoli*)

P45

CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE

Martin T., Lin Y., Agha M., Cohen A., Htut M., Stewart A., Hari P., Berdeja J., Madduri D., Usmani S., Yeh T.M., Allred A., Olyslager Y., Banerjee A., Goldberg J., Schechter J., Jackson C., Deraedt W., Gries K., Fastenau J., Wu X., Carrasco-Alfonso M., Akram M., Hossain F., Jakubowiak A., Jagannath S. (*San Francisco, Rochester, Pittsburgh, Philadelphia, Duarte, Toronto, Milwaukee, Nashville, New York, Charlotte, Raritan, Spring House, Beerse, Piscataway, Chicago*)

P46

POMALIDOMIDE/DEXAMETHASONE COMBINATIONS ARE AN EFFECTIVE SALVAGE REGIMEN FOR MULTIPLE MYELOMA (MM) PATIENTS RELAPSED AND/OR REFRACTORY TO DARATUMUMAB (DARA)

Brioli A., Mancuso K., Binder M., Ernst T., Hilgendorf I., Zamagni E., Heidel F., Stauch T., Hochhaus A., von Lilienfeld-Toal M. (*Jena, Bologna, Halle*)

P47

EVOLVING OUTCOMES IN MM REAL-WORLD PRACTICE: 20-YEARS SINGLE CENTER EXPERIENCE

Bianco O., Bellofiore C., Romano A., Leotta V., Del Fabro V., Elia F., Di Raimondo F., Conticello C. (*Catania*)

P48

EARLY OLIGOSECRETORY/FREE LIGHT CHAIN ESCAPE AND THE IMPORTANCE OF REGULAR SFLC ASSESSMENT. A REAL-LIFE UNICENTRIC RETROSPECTIVE STUDY

Markovic U., Romano A., Del Fabro V., Bellofiore C., Bulla A., Di Raimondo F., Conticello C. (*Catania*)

P49

A HEALTHCARE PROFESSIONAL SURVEY TO UNDERSTAND PATIENT ASSESSMENT, MANAGEMENT AND ADMINISTRATION PRACTICES IN THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WITH CARFILZOMIB

Wetten S., Di Pietrantonio K., Sumners E., Trewartha F., Fowler G., Brailean A. (*Uxbridge, Bollington*)

P50

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

Cerchione C., Martinelli G., Nappi D., Pareto A.E., Di Perna M., Ferrara K., Musuraca G., Lucchesi A., Pane F., Catalano L. (*Meldola, Napoli*)

P51

IMMUNOTHERAPY IN MULTIPLE MYELOMA: EXPERIENCE OF THE MULTIPLE MYELOMA

GIMEMA LAZIO GROUP

Vozella F., Siniscalchi A., Rizzo M., Za T., Antolino G., Coppetelli U., Piciocchi A., Andriani A., Annibali O., De Rosa L., Cimino G., La Verde G., De Stefano V., Cantonetti M., Caravita di Toritto T., Petrucci M.T. (*Roma*)

P52

LONG-TERM CONTROL OF DISEASE IN MYELOMA PATIENTS TREATED AT THE SECOND RELAPSE WITH MONOCLONAL ANTIBODIES: A REAL-WORLD SINGLE CENTER EXPERIENCE

Markovic U., Romano A., Leotta V., Del Fabro V., Bellofiore C., Bianco O., Curto Pelle A., Di Raimondo F., Conticello C. (*Catania*)

P53

EXTRAMEDULLARY MULTIPLE MYELOMA OF THE ORAL CAVITY: A MONOCENTRIC CASE SERIES

Brescini M., Fazio F., Petrucci M.T. (*Roma*)

P54

OUTCOMES IN MULTIPLE MYELOMA THAT DEBUTS WITH PLASMACYTOMA: AN OBSERVATIONAL STUDY

Pinzón S., Bakali S., Izquierdo I., García J., Almanzar H.P., Hernández C., Gómez A., Martin-Consuegra S., Moreno M., González E., Rubio A., Osuna C., Iborra A., Delgado P. (*Zaragoza*)

P55

USE OF DARATUMUMAB IN RELAPSE/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE REAL WORLD

Solé-Rodríguez M., Zapata-Bautista R., Domínguez-Rodríguez J.F. (*Huelva*)

P56

BELANTAMAB MAFODOTIN IN HEAVILY TREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A CASE-SERIES FROM A REAL-LIFE EXPERIENCE

Fazio F., Brescini M., Lapietra G., Petrucci M.T. (*Roma*)

4. SPECIAL CONDITIONS

P57

NATURAL HISTORY OF SKELETAL RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA AT DIAGNOSIS AND AT FIRST RELAPSE: RESULTS FROM A SINGLE CENTER STUDY IN 620 PATIENTS WHO RECEIVED NOVEL ANTIMYELOMA AGENTS

Terpos E., Kanellias N., Kastritis E., Gavriatopoulou M., Koutoulidis V., Ntanasis-Stathopoulos I., Papanota A.M., Fotiou D., Migkou M., Eleutherakis-Papaikovou E., Malandrakis P., Bagratuni T., Roussou M., Moulopoulos L.A., Dimopoulos M.A. (*Athens*)

P58

WHOLE BODY LOW DOSE CT IN NEWLY DIAGNOSED MULTIPLE MYELOMA: DIAGNOSTIC VALUE OF PERIPHERAL MEDULLARY PATTERNS OF ATTENUATION

Terpos E., Koutoulidis V., Ntanasis-Stathopoulos I., Gavriatopoulou M., Zagouri F., Klapa I., Boultadaki A., Malandrakis P., Papanota A.M., Fontara S., Kastritis E., Moulopoulos L.A., Dimopoulos M. (*Athens*)

P59

CORONAVIRUS DISEASE (COVID-19) IN PATIENTS WITH MULTIPLE MYELOMA:
REPORTED BY THE MULTIPLE MYELOMA GIMEMA LAZIO GROUP

Fazio F., Lapietra G., Anaclerico B., Annibali O., Antolino G., Cupelli L., Brescini M., De Rosa L., Fiorini A., Franceschini L., Gumennyuk S., Poggiali R., Rosati S., Za T., Piciocchi A., Petracci M.T. (*Roma, Viterbo, Latina, Frosinone*)

P60

MANAGEMENT OF HEMATOLOGICAL CANCER PATIENTS IN SARS-COV-2 PANDEMIC:
FOCUS ON MULTIPLE MYELOMA PATIENTS IN A SICILIAN HOSPITAL

Del Fabro V., Romano A., Bellofiore C., Bulla A., Garibaldi B., Markovic U., Di Raimondo F., Conticello C. (*Catania*)

P61

TELEMONITORING IN HAEMATO-ONCOLOGICAL PATIENTS: HIT OR MISS?

Hradska K., Popkova T., Skorupova M., Mihalyova J., Jelinek T., Navratil M., Benkova K., Plonkova H., Zuchnicka J., Gumulec J., Hajek R. (*Ostrava*)

P62

EMPOWERING PATIENTS IN THE FACE OF A PANDEMIC – A MULTI-DISCIPLINARY REMOTE MONITORING CLINIC FOR A PATIENT-CENTRED APPROACH IN MYELOMA

Lecat C., Camilleri M., DeSilva D., McCourt O., Worthington S., Smith M., Hart A., Uddin I., Roche C., Fisher A., Yong K. (*London*)

P63

IMPLICATIONS OF INTERLEUKIN-6 (IL-6)-BLOCKADE FOR SEVERE COVID-19 INFECTION IN PATIENTS WITH MULTIPLE MYELOMA

Sgherza N., Curci P., Strafella V., Rizzi R., Musto P. (*Bari*)

P64

AUTOGOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS OVER 60 YEARS:
MEL200 VERSUS MEL140

Solé-Rodríguez M., Zapata-Bautista R., Palma-Vallellano A. (*Huelva*)

P65

PEGFILGRASTIM VERSUS FILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN TREATMENT WITH POMALIDOMIDE-DEXAMETHASONE

Cerchione C., Martinelli G., Nappi D., Pareto A.E., Lucchesi A., Musuraca G., Ronconi S., Pane F., Catalano L. (*Meldola, Napoli*)

P66

POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA

Cerchione C., Martinelli G., Nappi D., Pareto A.E., Di Perna M., Ferrara K., Ronconi S., Cangini D., Giannini M.B., Di Battista V., Pane F., Catalano L. (*Meldola, Napoli*)

P67

SAFETY AND EFFICACY OF RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS INFUSION OF IMMUNOGLOBULINS IN PATIENTS WITH MULTIPLE MYELOMA

Pavan L., Barilà G., Vedovato S., Leoncin M., Berno T., Branca A., Piazza F., Semenzato G., Zambello R. (*Padova*)

P68

USE OF DIRECT ORAL ANTICOAGULANTS AS PROPHYLAXIS OR TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH MULTIPLE MYELOMA ON IMMUNOMODULATORY DRUGS

Aguilar C., Dueñas A.B., Sevil F., Dominguez C. (*Soria*)

P69

USE OF IBRUTINIB OFF-LABEL IN WALDENSTROM'S MACROGLOBULINEMIA
CHEMOTHERAPY REFRACTORY PATIENTS

Solé-Rodríguez M., Díaz-Roldán B., Zapata-Bautista R. (*Huelva*)

P70

TRIPLE HEMATOLOGICAL DIAGNOSIS: A CLINICAL CHALLENGE

Pinzón S., García J., Bakali S., Hernández C., Gómez A., Martín-Consuegra S.,
Moreno M., González E., Rubio A., Osuna C., Iborra A., Delgado P. (*Zaragoza*)

P71

EUROPEAN HEMATOLOGY ASSOCIATION (EHA) SCIENTIFIC WORKING GROUPS:

THE POWER OF COLLABORATION

Cerisoli F., Gribben J., Sonneveld P., Dreyling M. (*The Hague, Rotterdam, London, Munich*)

P72

PLASMA CELL LEUKEMIA: ABOUT A CATASTROPHIC CASE

Pinzón S., Bakali S., García A., Diez R., Anso V., Hernández C., Gómez A.,
Martín-Consuegra S., Moreno M., González E., Delgado P. (*Zaragoza*)

Acknowledgments

PLATINUM SPONSORS



Celgene | Bristol Myers Squibb[®]
Company



GOLD PLUS SPONSORS



GOLD SPONSORS



2nd Meeting
European Myeloma Network
Virtual | March 3-6, 2021

Enjoy the virtual experience!

SCIENTIFIC BOARD

Mario Boccadoro (Italy)
Hermann Einsele (Germany)
Maria-Victoria Mateos (Spain)
Philippe Moreau (France)
Pieter Sonneveld (The Netherlands)

SCIENTIFIC PROGRAM COORDINATORS

Pieter Sonneveld (The Netherlands)
Sonja Zweegman (The Netherlands)

SCIENTIFIC SECRETARIAT

Francesca Gay (Italy)
Niels van de Donk (The Netherlands)

ORGANIZING SECRETARIAT

Studio E.R. Congressi
Via De' Poeti, 1/7 - 40124 Bologna - Italy
Ph +39 051 4210559
Fax +39 051 4210174
E-mail: emnmeeting@ercongressi.it
www.ercongressi.it

2nd Meeting
European Myeloma Network
Virtual | March 3-6, 2021